For an adult with type 2 diabetes, how do empagliflozin and dapagliflozin compare in terms of efficacy, cardiovascular outcomes, dosing, and renal eligibility?

Empagliflozin and Dapagliflozin Are Clinically Interchangeable for Type 2 Diabetes

Both empagliflozin and dapagliflozin demonstrate equivalent cardiovascular and renal outcomes in patients with type 2 diabetes, with the primary distinction being their renal eligibility thresholds rather than efficacy differences. 1

Cardiovascular Outcomes: No Meaningful Difference

The landmark cardiovascular outcomes trials—EMPA-REG OUTCOME for empagliflozin and DECLARE-TIMI 58 for dapagliflozin—both demonstrated significant cardiovascular benefits, though with slightly different effect sizes that are not clinically meaningful when compared head-to-head 2:

• MACE reduction: Empagliflozin 14% vs. dapagliflozin showed non-inferiority
• Cardiovascular death: Empagliflozin 38% reduction (HR 0.62) vs. dapagliflozin comparable effects
• Heart failure hospitalization: Both reduced by approximately 30% (empagliflozin HR 0.65, dapagliflozin HR 0.73)

Real-world comparative effectiveness studies consistently show no significant differences between the two agents. The largest Scandinavian cohort study of 199,371 patients found identical risks for major cardiovascular events (HR 1.02,95% CI 0.97-1.08), heart failure (HR 1.05,95% CI 0.97-1.14), and serious renal events (HR 0.97,95% CI 0.87-1.07) 3. A Korean nationwide study of 145,504 patients similarly demonstrated comparable composite cardiovascular outcomes (HR 0.93,95% CI 0.855-1.006) 4.

Renal Outcomes: Equivalent Protection

Both agents provide robust renal protection with similar mechanisms and outcomes 5, 1:

• Albuminuria reduction: Both reduce progression by 27-39%
• eGFR preservation: Similar rates of slowing eGFR decline
• ESRD prevention: Comparable risk reductions in major trials

The DAPA-CKD and CREDENCE trials for dapagliflozin, and EMPA-KIDNEY for empagliflozin, all demonstrated 30-40% reductions in composite renal outcomes. 5, 1 One observational study suggested modestly higher ESKD risk with dapagliflozin (HR 1.28), but this requires cautious interpretation given potential residual confounding 6.

Critical Dosing and Renal Eligibility Differences

The most clinically relevant distinction is the eGFR threshold for initiation 1, 7:

Empagliflozin:

• Standard dose: 10 mg daily
• Initiation threshold: eGFR ≥20 mL/min/1.73 m² (based on EMPEROR trials)
• FDA labeling: Not recommended for glycemic control if eGFR <45 mL/min/1.73 m²
• Continue therapy: Can continue below initiation threshold once started

Dapagliflozin:

• Standard dose: 10 mg daily
• Initiation threshold: eGFR ≥25 mL/min/1.73 m² for CKD indication, ≥20 mL/min/1.73 m² per updated guidelines 1
• FDA labeling: May initiate at eGFR ≥25 mL/min/1.73 m²
• Continue therapy: Can continue to eGFR <20 mL/min/1.73 m² once started 8

For patients with eGFR 20-25 mL/min/1.73 m², empagliflozin has broader FDA approval based on EMPEROR trial data, though updated ADA/KDIGO guidelines now support both agents at eGFR ≥20 mL/min/1.73 m². 1

Practical Selection Algorithm

Choose based on renal function and formulary considerations:

1. eGFR ≥45 mL/min/1.73 m²: Either agent is appropriate; select based on cost/formulary
2. eGFR 25-44 mL/min/1.73 m²: Either agent appropriate for cardiorenal protection (not glycemic control)
3. eGFR 20-24 mL/min/1.73 m²: Empagliflozin has stronger regulatory support, though both may be used per guidelines 1
4. eGFR <20 mL/min/1.73 m²: Neither should be initiated; may continue if already established

Safety Profile: Essentially Identical

Both agents share the same class-wide adverse effects 1, 8:

• Genital mycotic infections: 6% vs. 1% placebo (similar between agents)
• Volume depletion: Low absolute risk, especially at lower eGFR
• Euglycemic DKA: Rare but serious; maintain low-dose insulin in insulin-requiring patients
• Hypoglycemia: Only when combined with insulin/sulfonylureas
• Fractures: Theoretical concern in advanced CKD, but not consistently demonstrated

No clinically meaningful safety differences exist between empagliflozin and dapagliflozin in head-to-head comparisons. 3, 4

Common Pitfalls to Avoid

1. Don't discontinue when eGFR drops acutely after initiation: The initial 5 mL/min decline is expected and protective long-term 1
2. Don't withhold in advanced CKD: Benefits extend to eGFR ≥20 mL/min/1.73 m² for cardiorenal protection
3. Don't expect glycemic benefit at eGFR <45 mL/min/1.73 m²: Use for cardiorenal protection, not glucose lowering 1
4. Institute sick day protocols: Hold during acute illness to prevent volume depletion and DKA 1

Glycemic Efficacy: Minimal Practical Difference

One small prospective study suggested greater HbA1c reduction with empagliflozin 25 mg versus dapagliflozin 10 mg (-1.4% vs. -1.1%, p<0.001) 9. However, this compared different doses and the clinical significance is marginal. For practical purposes, glycemic efficacy is equivalent when using standard doses (empagliflozin 10 mg, dapagliflozin 10 mg).

The bottom line: Select based on formulary cost and renal function thresholds rather than perceived efficacy differences, as both agents provide equivalent cardiorenal protection in type 2 diabetes. 3, 4, 10